Jump to main content
Jump to site search


Synthesis and characterization of potential stereoisomeric and degradation impurities of ulipristal acetate

Author affiliations

Abstract

Ulipristal acetate (UPA) was developed by Laboratoire HRA Pharma, France and approved by the FDA for emergency contraception in August 2010. Though several methods have been developed for the synthesis of UPA, the steroidal impurities would appear inevitably and have not been reported in detail. In this work, several stereoisomeric and N,N-didemethylated impurities of UPA were analyzed and synthesized. The stereoisomers were obtained through an efficient and practical approach, and the structure of the key stereoisomer U-1 was confirmed by single-crystal X-ray analysis. Our research would be important and valuable for the quality control of UPA manufacturing.

Graphical abstract: Synthesis and characterization of potential stereoisomeric and degradation impurities of ulipristal acetate

Back to tab navigation

Supplementary files

Publication details

The article was received on 28 Jan 2019, accepted on 07 Feb 2019 and first published on 08 Feb 2019


Article type: Research Article
DOI: 10.1039/C9QO00144A
Citation: Org. Chem. Front., 2019, Advance Article

  •   Request permissions

    Synthesis and characterization of potential stereoisomeric and degradation impurities of ulipristal acetate

    P. Xu, H. Luan, B. Yu, Y. Tu, Y. Sun, W. Chen, X. Xu, R. Ge, J. Wang, Z. Li and J. Bian, Org. Chem. Front., 2019, Advance Article , DOI: 10.1039/C9QO00144A

Search articles by author

Spotlight

Advertisements